Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts
OBJECTIVES:
- Determine the survival of patients with colon cancer, breast cancer, or melanoma with
minimal residual disease after surgical resection treated with maintenance
immunotherapy using Corynebacterium granulosum P40.
- Determine leucocyte adherence inhibition, an indication of metastases, over time in
patients treated with this regimen.
OUTLINE: This is a multicenter study. Patients are stratified by center and are matched with
case-controls by disease type and stage.
Beginning 2 weeks after surgical resection, patients receive Corynebacterium granulosum P40
subcutaneously weekly for 6 weeks, followed by rest for 3 months. Treatment continues for
life.
Patients are followed for survival.
PROJECTED ACCRUAL: Not specified
Interventional
Primary Purpose: Treatment
Recurrence
No
Hugo Omar De Carli, MD
Study Chair
Centro Oncologico de Excelencia
United States: Federal Government
CDR0000072435
NCT00002455
April 1971
Name | Location |
|---|
